Trulicity
E133647
Trulicity is a prescription GLP-1 receptor agonist medication used to improve blood sugar control in adults with type 2 diabetes.
All labels observed (5)
| Label | Occurrences |
|---|---|
| Trulicity canonical | 2 |
| GLP-1 receptor agonists | 1 |
| Victoza | 1 |
| diabetes drug Trulicity | 1 |
| dulaglutide | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T1168569 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Trulicity Context triple: [Eli Lilly and Company, notableProduct, Trulicity]
-
A.
Denesuline
Denesuline are a First Nations people of the larger Dene cultural and linguistic group, traditionally inhabiting subarctic regions of northern Canada.
-
B.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
C.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
D.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
E.
Lucentis
Lucentis is a prescription anti-VEGF biologic drug used to treat several serious eye diseases, including wet age-related macular degeneration and diabetic macular edema, by inhibiting abnormal blood vessel growth in the retina.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Trulicity Target entity description: Trulicity is a prescription GLP-1 receptor agonist medication used to improve blood sugar control in adults with type 2 diabetes.
-
A.
Denesuline
Denesuline are a First Nations people of the larger Dene cultural and linguistic group, traditionally inhabiting subarctic regions of northern Canada.
-
B.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
C.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
D.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
E.
Lucentis
Lucentis is a prescription anti-VEGF biologic drug used to treat several serious eye diseases, including wet age-related macular degeneration and diabetic macular edema, by inhibiting abnormal blood vessel growth in the retina.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
GLP-1 receptor agonist
ⓘ
antidiabetic drug ⓘ medication ⓘ |
| canAffect | body weight ⓘ |
| canBeUsedWith |
insulin
ⓘ
metformin ⓘ sulfonylureas ⓘ |
| dosingFrequency | once weekly ⓘ |
| hasActiveIngredient | dulaglutide ⓘ |
| hasATCCode | A10BJ05 ⓘ |
| hasBoxedWarning | risk of thyroid C-cell tumors in rodents ⓘ |
| hasBrandOwner | Eli Lilly and Company ⓘ |
| hasDosageForm |
pre-filled pen
ⓘ
solution for injection ⓘ |
| hasDrugClass | glucagon-like peptide-1 receptor agonist ⓘ |
| hasGenericName | dulaglutide ⓘ |
| hasManufacturer | Eli Lilly and Company ⓘ |
| hasRisk |
hypoglycemia when used with insulin or sulfonylurea
ⓘ
pancreatitis ⓘ |
| hasTherapeuticArea |
diabetology
ⓘ
endocrinology ⓘ |
| indicationRegion |
European Union
ⓘ
United States ⓘ
linked to:
United States of America
|
| isAdministered | once weekly on the same day each week ⓘ |
| isAdministeredBy |
subcutaneous route in abdomen
ⓘ
subcutaneous route in thigh ⓘ subcutaneous route in upper arm ⓘ |
| isApprovedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| isContraindicatedIn |
patients with multiple endocrine neoplasia syndrome type 2
ⓘ
patients with personal or family history of medullary thyroid carcinoma ⓘ |
| isIndicatedFor | adults with type 2 diabetes ⓘ |
| isNotIndicatedFor |
diabetic ketoacidosis
ⓘ
type 1 diabetes ⓘ |
| isPrescriptionOnly | true ⓘ |
| isUsedAs | adjunct to diet and exercise ⓘ |
| isUsedFor |
improving glycemic control
ⓘ
reducing blood sugar levels ⓘ type 2 diabetes mellitus ⓘ |
| mayCause |
abdominal pain
ⓘ
decreased appetite ⓘ diarrhea ⓘ nausea ⓘ vomiting ⓘ |
| mechanismOfAction |
GLP-1 receptor agonism
ⓘ
enhances glucose-dependent insulin secretion ⓘ slows gastric emptying ⓘ suppresses inappropriate glucagon secretion ⓘ |
| regulates | blood glucose levels ⓘ |
| routeOfAdministration | subcutaneous injection ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Trulicity Description of subject: Trulicity is a prescription GLP-1 receptor agonist medication used to improve blood sugar control in adults with type 2 diabetes.
Referenced by (6)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: Trulicity
linked to: Trulicity
linked to: Trulicity
linked to: Trulicity
subject linked to:
Eli Lilly and Company (former executive roles prior to governorship)